Wren Capital

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to reduce variability in patient populations and identify individuals with similar underlying neurobiology. This targeted approach aims to enhance the research and development of neuroscience drugs in areas with significant unmet medical needs, ultimately advancing treatment options for these complex conditions.

Spotta Ltd is a company based in Cambridge, United Kingdom, that specializes in developing smart pest detection systems for the hospitality industry. Founded in 2018, Spotta offers an innovative battery-powered insect monitoring sensor designed to detect bed bug infestations at an early stage. The sensor alerts users when bed bugs are detected and analyzes the findings to ensure notifications are sent only for genuine incidents. This proactive approach allows hotels and lodging providers to prevent bed bugs from entering guest rooms, facilitating easier and more cost-effective treatment options. Spotta's technology aims to enhance guest comfort and safety while minimizing the impact of bed bug infestations on the hospitality sector.

MitoRx Therapeutics is a biotechnology company focused on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company specializes in creating mitochondrial-protective treatments for a range of conditions, including neuromuscular disorders, metabolic diseases, and dementia. By targeting the underlying mitochondrial issues associated with these challenging diseases, MitoRx Therapeutics seeks to enable healthcare professionals to halt the progression of conditions such as dystrophy and neurodegeneration. In addition to its internal research on rare indications, the company also collaborates on broader health issues, positioning itself as a key player in the field of mitochondrial medicine.

Bastion Therapeutics is a preclinical stage biotechnology company focused on developing innovative anti-inflammatory cell therapies. Utilizing its proprietary platform technology, the company aims to enhance regulatory T cells (Tregs) within the immune system. By targeting neuroinflammation in critical areas of the central nervous system, Bastion Therapeutics seeks to protect neurons and improve synaptic connectivity, ultimately helping patients to maintain cognitive function and prevent deterioration. Through its research and development efforts, the company is positioning itself to address significant unmet medical needs in the realm of neuroinflammatory conditions.

PharmEnable Limited is a drug discovery company based in Cambridge, United Kingdom, that specializes in the design of small molecule drugs through the integration of medicinal chemistry and artificial intelligence computational methods. Established in 2016, the company has created a rapid and cost-effective approach to identify superior chemical starting points, thereby facilitating the discovery of essential new medicines.

MitoRx Therapeutics is a biotechnology company focused on developing innovative therapeutics aimed at reversing mitochondrial dysfunction. The company specializes in creating mitochondrial-protective treatments for a range of conditions, including neuromuscular disorders, metabolic diseases, and dementia. By targeting the underlying mitochondrial issues associated with these challenging diseases, MitoRx Therapeutics seeks to enable healthcare professionals to halt the progression of conditions such as dystrophy and neurodegeneration. In addition to its internal research on rare indications, the company also collaborates on broader health issues, positioning itself as a key player in the field of mitochondrial medicine.

AdaptTech Ltd., established in 2015 and based in Birmingham, UK, is a biomedical company specializing in innovative, smart wearable technologies designed to enhance the lives of individuals with physical limitations, particularly those who have experienced lower limb loss. The company's flagship products include the INSIGHT Scanner, which rapidly creates a 3D model of prosthetic sockets; the INSIGHT Wearable, real-time bio-data tracker between the stump and socket; and the INSIGHT App, providing anytime access to results. AdaptTech aims to empower clinicians with improved socket fitting and monitoring methods, ultimately improving the quality of life for users.

Centauri Therapeutics is a biotechnology company focused on the discovery and development of innovative immunotherapeutics aimed at addressing life-threatening diseases. Utilizing its proprietary Alphamer technology, Centauri creates chemically synthesized molecules that redirect naturally occurring antibodies to specific pathogens, enhancing the body's immune response. The company's dual-action approach involves directly targeting cell surface antigens while employing a glycan effector domain to stimulate a robust polyclonal immune response. This mechanism promotes cell death via enhanced complement fixation, antibody-dependent cellular cytotoxicity, and phagocytosis by myeloid cells. Centauri has demonstrated strong pre-clinical results, showcasing significant improvements in complement fixation and opsonophagocytosis for both anti-bacterial and oncology therapeutics, as well as in vivo proof-of-concept data across various infection models.

Tay Therapeutics is a biotechnology company focused on drug discovery for the treatment of inflammatory conditions, particularly skin diseases. The company is dedicated to developing innovative topical and oral therapies that serve as alternatives to traditional steroid creams, which are commonly prescribed for conditions like psoriasis and eczema. Recognizing the limitations and potential side effects associated with steroid treatments, Tay Therapeutics aims to deliver safe and effective medications that improve patient outcomes. By prioritizing the needs of patients suffering from skin diseases, the company seeks to revolutionize the therapeutic landscape in this area.

Monument Therapeutics is a biotechnology company focused on developing innovative drugs for serious diseases affecting the central nervous system. The company employs proprietary digital biomarkers to reduce variability in patient populations and identify individuals with similar underlying neurobiology. This targeted approach aims to enhance the research and development of neuroscience drugs in areas with significant unmet medical needs, ultimately advancing treatment options for these complex conditions.

AdaptTech Ltd., established in 2015 and based in Birmingham, UK, is a biomedical company specializing in innovative, smart wearable technologies designed to enhance the lives of individuals with physical limitations, particularly those who have experienced lower limb loss. The company's flagship products include the INSIGHT Scanner, which rapidly creates a 3D model of prosthetic sockets; the INSIGHT Wearable, real-time bio-data tracker between the stump and socket; and the INSIGHT App, providing anytime access to results. AdaptTech aims to empower clinicians with improved socket fitting and monitoring methods, ultimately improving the quality of life for users.

Antiverse is an innovative antibody discovery company that aims to transform drug development by leveraging a unique platform combining structural biology, machine learning, and medicine. The company specializes in predicting antibody-antigen binding and generating antibody drug candidates for challenging targets. By utilizing advanced machine learning techniques and cell-free protein synthesis, Antiverse enables pharmaceutical companies and contract research organizations to accelerate the discovery of antibody hits, ultimately making the drug development process more efficient and cost-effective. Through its commitment to advancing medical science, Antiverse seeks to create meaningful breakthroughs that can significantly impact patient lives.

Tay Therapeutics is a biotechnology company focused on drug discovery for the treatment of inflammatory conditions, particularly skin diseases. The company is dedicated to developing innovative topical and oral therapies that serve as alternatives to traditional steroid creams, which are commonly prescribed for conditions like psoriasis and eczema. Recognizing the limitations and potential side effects associated with steroid treatments, Tay Therapeutics aims to deliver safe and effective medications that improve patient outcomes. By prioritizing the needs of patients suffering from skin diseases, the company seeks to revolutionize the therapeutic landscape in this area.

Spotta Ltd is a company based in Cambridge, United Kingdom, that specializes in developing smart pest detection systems for the hospitality industry. Founded in 2018, Spotta offers an innovative battery-powered insect monitoring sensor designed to detect bed bug infestations at an early stage. The sensor alerts users when bed bugs are detected and analyzes the findings to ensure notifications are sent only for genuine incidents. This proactive approach allows hotels and lodging providers to prevent bed bugs from entering guest rooms, facilitating easier and more cost-effective treatment options. Spotta's technology aims to enhance guest comfort and safety while minimizing the impact of bed bug infestations on the hospitality sector.

Sarissa Biomedical, Ltd. is a biotechnology company based in Coventry, United Kingdom, founded in 2002. The company specializes in the development and production of advanced biosensors, particularly microelectrode electrochemical sensors, which are utilized to measure purines and other neuroactive chemicals. These sensors are designed for both in vitro and in vivo studies, catering to research and clinical diagnostic applications, particularly in the context of neurological activity and disorders. Sarissa Biomedical is also known for its point-of-care diagnostic device, which allows for the identification of stroke patients using finger-prick blood samples. This device leverages sophisticated software to monitor and control the measurement process, providing healthcare providers with accurate and reliable data. Sarissa Biomedical operates in various markets, including the United Kingdom, the United States, Canada, and Japan.

Procarta Biosystems Ltd is a biotechnology company based in Norwich, United Kingdom, that specializes in the development of innovative DNA-based antibacterials. Founded in 2007 as a spin-out from the John Innes Centre, Procarta focuses on addressing the critical challenge of drug-resistant bacterial strains, commonly referred to as superbugs. The company has created a versatile platform for antibiotic development, which includes proprietary nanoparticles designed to deliver oligonucleotides directly into bacterial pathogens. Their product range features targeted therapies such as MRSA snare, a solution for both topical and intravenous use; Broad-spectrum Gram-negative therapy snare, aimed at treating hospital-acquired infections; and Cdiff snare, which helps prevent the recurrence of Clostridium difficile infections. With a commitment to combating the rising threat of antibiotic resistance, Procarta Biosystems is positioned to enhance therapeutic options in clinical settings.

Oxford Space Systems Limited is a Harwell, United Kingdom-based company that specializes in the development and manufacturing of deployable hardware structures for space environments. Founded in 2013, the company has gained recognition for its innovative designs, including deployable antennas, panels, hinge systems, and composite linear boom systems. Utilizing advanced techniques such as origami and proprietary materials, Oxford Space Systems creates solutions that are lighter, more efficient, and cost-effective compared to traditional alternatives, catering to the global satellite industry. The company's AstroTube Boom set a record for the fastest product development from concept to successful deployment in under 30 months. With a team of 18 professionals, combining diverse backgrounds and over a century of collective experience in the space sector, Oxford Space Systems has engaged in various collaborative projects with leading European satellite manufacturers and has secured commercial contracts across Asia and the US. The company operates from a state-of-the-art facility within the Harwell Space Cluster, equipped to meet the security requirements necessary for defense and security contracts.

PredictImmune Ltd is a biotechnology company based in Cambridge, United Kingdom, focused on developing prognostic tests for immune-mediated inflammatory diseases. Established in 2017, the company offers PredictSURE IBD, a diagnostic tool designed to identify patients with Inflammatory Bowel Disease (IBD), including Crohn’s disease and ulcerative colitis, who are at risk of severe, relapsing disease. This simple lab test requires only a small blood sample and provides critical insights that enable healthcare providers to tailor early biologic therapies for at-risk patients. By delivering personalized treatment options, PredictImmune aims to improve disease management and clinical outcomes for individuals suffering from IBD, addressing an important need recognized by physicians, patients, and payors alike.

Smartpipe is creating the only global, real-time, privacy compliant and completely secure data ecosystem for the monetisation of network operators’ rich customer data. Their patent-protected solution enables network operators, data providers, advertising agencies and brands to mutually benefit from high-quality, privacy compliant data assets, driving ROI for the entire data monetisation value chain. Made possible by a single technical integration into multiple ecosystems such as advertising, e-commerce and financial services, Smartpipe’s approach offers contextual, consented and anonymised customer data segments to data partners in real-time. This enables the delivery of highly relevant and targeted commercial communications to consumers. Smartpipe is backed by leading mobile, enterprise and SaaS investors, is headquartered in London with a software and development research centre in Cwmbran.

Keit Ltd. is a company specializing in the design and manufacture of advanced spectrometers and related instruments, catering to a wide range of applications from ultraviolet to far infrared rays. Incorporated in 2012 and headquartered in Didcot, United Kingdom, Keit is known for its innovative microFTS® design, a Fourier Transform Infrared (FTIR) spectrometer that is notably smaller, lighter, and more rugged than existing systems. Originally developed for space applications, the microFTS® is capable of operating in extreme environments and sets a new standard for real-time liquid-state analyses across various industries, including Pharmaceutical, Chemical, Oil & Gas, and Food & Beverage. Keit's products are also utilized for measuring signal levels, near line vibrations, and analyzing gas or liquid-borne species.

Spectral Edge Ltd, established in 2011 and headquartered in Cambridge, UK, specializes in image enhancement technologies. The company develops innovative solutions such as Phusion, which improves image and video quality by leveraging information outside the visible spectrum, and Eyeteq, a video personalization technology that enhances TV accessibility for color-blind individuals. Spectral Edge's products cater to consumer electronics manufacturers and service providers, serving applications like computational photography, security, and consumer electronics. As of 2019, the company operates as a subsidiary of Apple Inc.

Oxford Space Systems Limited is a Harwell, United Kingdom-based company that specializes in the development and manufacturing of deployable hardware structures for space environments. Founded in 2013, the company has gained recognition for its innovative designs, including deployable antennas, panels, hinge systems, and composite linear boom systems. Utilizing advanced techniques such as origami and proprietary materials, Oxford Space Systems creates solutions that are lighter, more efficient, and cost-effective compared to traditional alternatives, catering to the global satellite industry. The company's AstroTube Boom set a record for the fastest product development from concept to successful deployment in under 30 months. With a team of 18 professionals, combining diverse backgrounds and over a century of collective experience in the space sector, Oxford Space Systems has engaged in various collaborative projects with leading European satellite manufacturers and has secured commercial contracts across Asia and the US. The company operates from a state-of-the-art facility within the Harwell Space Cluster, equipped to meet the security requirements necessary for defense and security contracts.

Monica Healthcare, based in Nottingham, United Kingdom, is a manufacturer of advanced fetal monitoring devices aimed at improving obstetric care. Founded in 2005, the company specializes in innovative wearable technologies that utilize wireless systems to monitor maternal heart rate, fetal heart rate, and uterine activity. One of its key products is The Novii, a single-use wireless patch designed for both hospital and home use. Monica Healthcare's devices are intended to enhance the birth experience for midwives, labor and delivery nurses, and expectant mothers, while also facilitating access to obstetric services. In addition to its product offerings, the company provides training, repairs, and support services to its customers. Since 2017, Monica Healthcare has been operating as a subsidiary of GE Healthcare.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

Momentum Bioscience Ltd is a biotechnology company specializing in the development of rapid diagnostic tests for critical clinical specimens. Established in 2005 and based in Cardiff, United Kingdom, the company utilizes its innovative Enzyme Mediated Amplification (EMA) technology to enable the universal detection of viable bacteria and fungi in under two hours, significantly reducing the time compared to traditional laboratory methods that can take 1 to 5 days. Momentum Bioscience's products are particularly valuable in neonatal care, emergency care, and critical care settings, as they specifically measure viable organisms, ensuring accurate detection of infections in blood and other normally sterile body fluids. The company is focused on advancing its suite of related technologies to enhance pathogen detection and support microbiology laboratories.

Captive Media Ltd is a British company that specializes in developing interactive entertainment systems for washrooms, particularly targeting male users. The company has created a patented urinal-mounted gaming console that features networked digital video screens positioned above men's urinals. These screens display a mix of engaging content and advertisements. The consoles utilize infra-red sensors to detect a user's stream, allowing them to interact with various games such as trivia quizzes and sports simulations without physical contact. Captive Media aims to enhance the average dwell time of 55 seconds at urinals by providing an entertaining and interactive experience. The units are designed to be retrofitted into existing washroom facilities, requiring only power and internet connectivity, and are built to be waterproof and vandal-proof. The company's installations can be found in a range of venues, including bars, clubs, hotels, sports facilities, airports, shopping malls, and corporate offices throughout the UK and the EU. Founded in 2007 and based in Chelmsford, the company serves brands and agencies by leveraging this unique advertising medium.

Blu Wireless Technology is a Silicon IP company specializing in the development of advanced 60GHz baseband technology aimed at supporting the WiGig standard and enhancing 4G backhaul applications. The company's innovative solutions are designed for power-sensitive mobile applications and long-range access points, enabling data rates exceeding multiple Gbps over distances greater than 300 meters. By licensing its technology as a comprehensive System IP solution, Blu Wireless Technology provides clients in the telecom and semiconductor markets with the tools necessary to build efficient 5G infrastructure. Their expertise in mmWave silicon IP, coupled with a deep understanding of market dynamics, allows them to deliver unique, cost-effective products that distinguish their partners and customers from competitors.

Horizon Discovery Group plc is a UK-based life science company specializing in gene editing and gene modulation technologies that advance research and clinical applications in human health. Established in 2007 and headquartered in Cambridge, the company designs, manufactures, and applies a wide array of gene editing tools, including custom-made and off-the-shelf RNA interference (RNAi) reagents, CRISPR reagents, and various cell models. Horizon Discovery offers services such as pooled and arrayed CRISPR screens, drug screens, and immunology assays, catering to the needs of academic research labs, biopharmaceutical companies, and contract research organizations. Its extensive product catalog includes over 1,000,000 cell and reagent products that help scientists investigate genetic anomalies associated with diseases like cancer. The company has formed strategic partnerships with various institutions to enhance its offerings, including collaborations for developing innovative gene editing technologies. As of December 2020, Horizon operates as a subsidiary of PerkinElmer (UK) Holdings Ltd.

Cytox Limited is a company focused on developing innovative products and services for the diagnosis and treatment of neurodegenerative disorders, particularly Alzheimer's disease. Established in 2004 and headquartered in Birmingham, UK, with additional offices in Manchester and Oxford, Cytox has created a genetic-based blood test that assesses the risk and early diagnosis of Alzheimer's disease, which currently affects millions worldwide. The company employs cellular and genetic assays to identify early cell cycle deficits in patients, aiding pharmaceutical and biotechnology companies in clinical trials and drug development for Alzheimer's and mild cognitive impairment. Cytox's strategic partnership with Affymetrix, part of Thermo Fisher Scientific, enhances its capabilities in delivering these assessments and supporting the development of novel therapeutics.

LumeJet Print Technologies Limited is a company based in Coventry, United Kingdom, that specializes in the design, development, and manufacture of ultra-high resolution printers tailored for production environments. These printers are utilized for various applications, including layflat books, fine art prints, pitches and proposals, book jackets, and wedding albums. Additionally, LumeJet's technology supports inkless printing for labeling and packaging, printed electronics, and direct-write digital lithography for photomasking on printed circuit boards and flexible substrates. The company distributes its products through a network across Europe and North America. Established in 2009, LumeJet was previously known as LumeJet Limited before rebranding in September 2015.

Specle Limited is a London-based company that provides a centralized data platform for validated production and media information in the United Kingdom and Belgium. Established in 2006, Specle focuses on helping advertisers and creative agencies produce and deliver advertisements that meet specific technical requirements for print and digital media. The platform hosts validated advertising specifications for thousands of publications, allowing users to easily access the necessary guidelines for their projects. Advertisers can upload, validate, and deliver their ads directly to publishers, with some services enabling integration into the publication's flat plan. Specle is recognized for its user-friendly technology and commitment to customer support, catering to both one-time advertisers and large brands with high-volume needs.